|
|
Other links at Articles > Pharmacists |
| 3. |
Enzastaurin Shows Promise as Second- or Third-Line Therapy in NSCLC
|
|
|
Enzastaurin, an oral serine/threonine kinase inhibitor, halted disease progression in some patients with metastatic non-small-cell lung cancer (NSCLC) in a single-arm, phase II study published in the March 1 issue of the Journal of Clinical Oncology. Reuters Health Information
|
|
|